Charles E. Lyon, MD (Shreveport, LA), David H Ren, MD, PhD (Shreveport, LA)

PURPOSE:

To investigate the visual outcome of intravitreal bevacizumab in treating subfoveal choroidal neovascularization due to age-retlated macular degeneration.

METHODS:

An open label, nonrandomized, prospective observational study was done on patients with subfoveal choroidal neovascularization due to AMD regardless of lesion type and previous treatment. After appropriate consents were obtained, patients received intravitreal bevacizumab (1.25mg) on a monthly basis for three consecutive injections. Outcome measurements including Snellen visual acuity, fluorescein angiogram, macular thickness by optical coherent tomography (OCT) were evaluated at subsequent office visit.

RESULTS:

Seventy-two eyes of 69 patients and 21 eyes of 20 patients had completed minimal 8-weeks and 12-weeks follow-ups respectively. Follow-ups are to continue at 4-week intervals up to one year.

CONCLUSION:

Preliminary results from this study demonstrated promising visual benefit effect of intravitreal bevacizumab therapy in treating subfoveal choroidal neovascularization due to AMD regardless of lesion type and previous treatment. Intravitreal bevacizumab injections were well-tolerated and had excellent shortterm safety profile.